Page 95«..1020..94959697..100110..»

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Posted: April 23, 2023 at 12:20 am

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 2:30 p.m. ET.

More here:
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Posted in Global News Feed | Comments Off on Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The…

Posted: April 23, 2023 at 12:20 am

Data accepted as AAN Late-Breaking Abstract Data accepted as AAN Late-Breaking Abstract

Excerpt from:
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The...

Posted in Global News Feed | Comments Off on Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The…

Ultimovacs ASA – Share Option Program

Posted: April 23, 2023 at 12:20 am

Oslo, 21 April 2023: On the basis of the approval by the General Meeting on 20 April 2023 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares to employees under a long-term incentive program, the Board of Directors has resolved to issue share options to employees in the Company.

Read the original:
Ultimovacs ASA - Share Option Program

Posted in Global News Feed | Comments Off on Ultimovacs ASA – Share Option Program

Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

Posted: April 23, 2023 at 12:20 am

Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds expected to fund planned operations of the combined company into mid-2024

Read the original here:
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

Posted in Global News Feed | Comments Off on Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

Arvinas to Present at Stifel Targeted Oncology Day

Posted: April 23, 2023 at 12:20 am

NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET.

See the article here:
Arvinas to Present at Stifel Targeted Oncology Day

Posted in Global News Feed | Comments Off on Arvinas to Present at Stifel Targeted Oncology Day

Tenaya Therapeutics to Participate at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Posted: April 23, 2023 at 12:20 am

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. Details of participation are as follows:

Originally posted here:
Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Posted in Global News Feed | Comments Off on Tenaya Therapeutics to Participate at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

AB Science announces the implementation of a new strategy and the launch of a capital increase

Posted: April 23, 2023 at 12:20 am

PRESS RELEASE

Read more from the original source:
AB Science announces the implementation of a new strategy and the launch of a capital increase

Posted in Global News Feed | Comments Off on AB Science announces the implementation of a new strategy and the launch of a capital increase

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Posted: April 23, 2023 at 12:20 am

CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today reports that on April 20, 2023, it received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) relating to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) as required under Section 5250(c) of Nasdaq Rules regarding the Qualification, Listing and Delisting of Companies (the “Nasdaq Listing Rules”). On March 31, 2023, the Company filed Notification of Late Filing on Form 12b-25 (the “Form 12b-25”), indicating that the filing of its Form 10-K will be delayed until after the completion of the accounting and disclosures related to the Company’s acquisition of a majority interest in NanoSynex, Ltd included in its Annual Report.

Follow this link:
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Posted in Global News Feed | Comments Off on Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Journal of Integrative Medicine | ScienceDirect.com by Elsevier

Posted: April 23, 2023 at 12:19 am

Journal of Integrative Medicine (JIM) is a peer-reviewed journal sponsored by Shanghai Association of Integrative Medicine and Shanghai Changhai Hospital, China. It is a continuation of the Journal of Chinese Integrative Medicine (JCIM), which was established in 2003 and published in Chinese language (The phonetic romanization of the Chinese title used by MEDLINE/PubMed is Zhong Xi Yi Jie He Xue Bao). Since 2013, JIM has been published in English language.

JIM is an interdisciplinary journal focusing on academic research and clinical studies in the field of integrative medicine. It aims to be a leading journal for studies in integrative medicine, and to promote communication and integration among traditional medicinal systems, complementary and alternative medicine (CAM), and conventional western medicine. The editorial board is committed to publishing high-quality papers on integrative medicine and creating an open forum in which the international scholarly community can exchange views, share research and clinical experience, discuss integrative medicine education, and confer about issues and problems in our various disciplines and in integrative medicine as a whole. The journal's international scope ensures that research and progress from all regions of the world are widely covered.

Topics covered include all aspects of integrative medicine, such as acupuncture and moxibustion, traditional Chinese medicine, Ayurvedic medicine, herbal medicine, homeopathy, nutrition, chiropractic, mind-body medicine, Taichi, Qigong, meditation, and any other modalities of CAM, as well as their integration with the conventional medicine.

Article types include, but are not limited to, randomized controlled and pragmatic trials, translational and patient-centered effectiveness outcome studies, case series and reports, clinical trial protocols, preclinical and basic science studies, systematic reviews and meta-analyses, papers on methodology and medical history or education, conference proceedings, editorials, commentaries, short reports, book reviews, and letters to the editor.

Headed by experienced and internationally recognized Editors-in-Chief and supported by a strong, internationally diverse team of editors, JIM benefits various groups, including clinical researchers, practitioners, academics and administrators worldwide in the field of medical healthcare. With its global reach, JIM looks to establish itself as an outstanding English language journal in its area of focus.

Benefits to Authors JIM is published both in print and online. The print issues are published bimonthly. However, the journal publishes articles in their full-citable form as soon as the final author corrections have been approved. Therefore, online publication is ahead of the printed journal at the website http://www.jcimjournal.com/jim/. JIM is indexed in MEDLINE/PubMed, ScienceDirect, Embase, Chemical Abstracts, CAB Abstracts, EBSCO, Western Pacific Region Index Medicus (WPRIM), Chinese Science Citation Database (CSCD) and China National Knowledge Infrastructure (CNKI). This ensures that articles published in JIM have the maximum exposure and visibility to the international scholarly community. JIM does not levy any submission fee or page charges to any author. We also provide many other author benefits, such as free PDFs, special discounts on Elsevier publications and much more. Please click here for more information on our author services.

Please see our Guide for Authors (https://www.elsevier.com/journals/journal-of-integrative-medicine/2095-4964/guide-for-authors) for information on article submission. If you require any further information or help, please visit our support pages: https://service.elsevier.com.

Read more from the original source:
Journal of Integrative Medicine | ScienceDirect.com by Elsevier

Posted in Integrative Medicine | Comments Off on Journal of Integrative Medicine | ScienceDirect.com by Elsevier

Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week? – InvestorsObserver

Posted: April 23, 2023 at 12:15 am

Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week?  InvestorsObserver

Read the rest here:
Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week? – InvestorsObserver

Page 95«..1020..94959697..100110..»